FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Pediatric Patients
The Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
label-modal-with-text-click-to-enlarge
Lorem Ipsem
- Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consectetur turpis vel risus tristique porta. Ut ut arcu accumsan nunc aliquam aliquam sed eget dui. Nam eu est non enim malesuada placerat. Etiam sit amet est porta magna iaculis venenatis at porttitor ligula.
Lorem ipsum
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aliquam consectetur turpis vel risus tristique porta. Ut ut arcu accumsan nunc aliquam aliquam sed eget dui. Nam eu est non enim malesuada placerat. Etiam sit amet est porta magna iaculis venenatis at porttitor ligula. Vestibulum eleifend diam ut enim tristique, non ultrices mauris gravida. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Vivamus vel varius sapien, nec finibus sem. Curabitur mollis rhoncus metus, in rutrum elit ultrices ut. Integer in imperdiet urna. Nulla placerat neque non lectus dapibus, eu vulputate nibh ullamcorper. Nunc nulla purus, dapibus ut volutpat at, ultrices eu magna. Quisque id facilisis velit, vitae posuere ipsum. Donec ut semper eros. Pellentesque non blandit enim.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission